Answers are grounded in this paper and cite their sources.
Mesenchymal stem cells (MSCs), as living biodrugs, have entered advanced phases of clinical assessment for cardiac function restoration in patients with myocardial infarction and heart failure. While MSCs are available from diverse tissue sources, bone-marrow-derived MSCs (BM-MSCs) remain the most well-studied cell type, besides umbilical-cord-derived MSCs (UC-MSCs). The latter offers advantages, including noninvasive availability without ethical considerations.
No takes yet. Share an insight, caveat, or question.
Safwan et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: